-

OmniGuide Receives 510(k) FDA Clearance for OTO-U Otology CO2 Surgical Fiber

BILLERICA, Mass.--(BUSINESS WIRE)--OmniGuide Holdings, a global healthcare technology leader in the design and delivery of innovative solutions for medical and surgical procedures, announces the commercial launch of the NEW OTO-U CO2 Laser System Fiber, designed for ENT and Otology Surgeons.

“OmniGuide continues to put patients first, invest in R&D, and deliver to the quality expected from our global brand. We understand the need for an everyday CO2 surgical fiber to complement our Flexible Instrument Portfolio” Matthew Henderson, President and CEO of OmniGuide Holdings “Next generation innovation is something OmniGuide can deliver. It is not just enabling the surgeon to get into a tighter space with more precision; it is also about helping to improve outcomes. The NEW OTO-U will be instrumental in our continued ability to help the doctors, and nurses we serve during this challenging time, enabling them to deliver for their patients.”

“OTO-U surgical fiber is the outcome of a multiple year investment in product development to meet the needs of the versatile CO2 surgical fiber user, with the right balance between price and performance, for everyday otology surgical procedures,” said Matthew Rice OmniGuide Managing Director. “We are excited to release OTO-U and look forward to its enhanced visibility and small 147 micron tissue target size in combination with our portfolio of advanced laser energy systems and Flexible Instruments for robotic surgery.”

About OmniGuide Inc.

OmniGuide, Inc. is a patient safety-focused medical technology innovator, providing a portfolio of advanced energy surgical tools to benefit clinicians and their patients alike. The company’s technologies deliver energy in a precise and electrically silent manner, resulting in the preservation of healthy tissue.

OmniGuide Surgical, a leader in flexible fiber CO2 laser technology, offers a range of products designed to enhance surgical accuracy, access and control for minimally invasive surgery, laparoscopy and robotic-assisted surgery.

Domain Surgical, by OmniGuide, Inc., provides a patented ferromagnetic technology designed to provide controlled cutting, coagulating and sealing of tissue with minimal tissue damage and no electrical current into the patients’ tissue.

LISA Laser Products GmbH, a leader in holmium and thulium laser technology, offers a wide range of products focused on improving clinical and patient outcomes in Urological surgical procedures.

Contacts

Giorgio Brusa
VP of Marketing
OmniGuide, Inc.
gbrusa@omni-guide.com
www.omni-guide.com

OmniGuide, Inc.


Release Versions

Contacts

Giorgio Brusa
VP of Marketing
OmniGuide, Inc.
gbrusa@omni-guide.com
www.omni-guide.com

More News From OmniGuide, Inc.

European Patent Office Grants OmniGuide with patent for its Laparoscopic Handpiece for FlexAssure CO2 Flexible Instruments and Fibers

BOSTON--(BUSINESS WIRE)--The European Patent Office granted OmniGuide with a new patent for its Laparoscopic Handpiece for FlexAssure CO2 Flexible Instruments (Patent Number 3193695). Laparoscopy is a surgical approach that allows a surgeon to access the inside of the human body without making large incisions. These procedures are widely adopted worldwide for their patient benefits including smaller surgical scars, quicker recovery, and decreased post procedure pain. OmniGuide FlexAssure CO2 Fl...

German Federal Ministry of Education and Research awards grants to fund a clinical trial for LISA Laser innovated “novel treatment of urolithiasis”

GÖTTINGEN, Germany--(BUSINESS WIRE)--On the 26th of August 2022, the German Federal Ministry of Education and Research selected a “novel approach for the treatment of urolithiasis” for funding (Grant No. 13GW0628). Urolithiasis (urinary stone formation) is a common disease affecting about 12% of the global population. Consequently, urolithiasis is a widespread disease with significant socioeconomic impact and is relevant to healthcare in terms of society and health policy. LISA Laser Products G...

OmniGuide Holdings Receives FDA Clearance for RevoLix™ HTL Hybrid Thulium Laser for the treatment of BPH and Stones

BILLERICA, Mass.--(BUSINESS WIRE)--OmniGuide Holdings (OGH) Today, the U.S. Food and Drug Administration cleared RevoLix™ HTL a family of pulsed and continuous wave Thulium YAG lasers is the foundation of RevoLix Therapy for urology patients undergoing BPH and Stone Management procedures. “The FDA's clearance reflects our confidence in our unique RevoLix™ HTL therapy and our efforts into surgical laser innovation, setting new standards in patients' safety,” said Dr. Samir Lamrini Global Directo...
Back to Newsroom